Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
about
Current status and perspectives of immune-based therapies for hepatocellular carcinomaRNA-Based Vaccines in Cancer ImmunotherapyModulation of GITR for cancer immunotherapyIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsMinireview: Regulatory T Cells and Ovarian Cancer.The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.Immunologic targeting of FOXP3 in inflammatory breast cancer cells.The soluble isoform of CTLA-4 as a regulator of T-cell responses.GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo.From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes.Clinical targeting of the TNF and TNFR superfamiliesEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Engineering nano- and microparticles to tune immunityHarnessing the immune system for the treatment of breast cancer.Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro.Apoptosis - an Ubiquitous T cell Immunomodulator.Tumor-altered dendritic cell function: implications for anti-tumor immunity.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapymRNA-based dendritic cell vaccines.Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?Potential approaches for more successful dendritic cell-based immunotherapy.Regulatory T cells and potential inmmunotherapeutic targets in lung cancer.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Immunotherapy for breast cancer: past, present, and future.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.mRNA Cancer Vaccines.mRNA vaccines - a new era in vaccinology.Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis.
P2860
Q26772326-FCC20A40-9FC9-4296-9B79-644232130945Q26776028-ECC663CD-404E-4423-9675-1E695AA873DEQ26853557-E1B11202-2B51-4A99-B9BD-A7A9F82DE333Q28072532-DED2EE5C-3CEA-48B7-ABB4-49D1893CD77AQ30244214-1BD2AA9F-EBD0-40CB-80E8-B7CFF9CD4619Q30317628-83413B84-3792-434E-AFF8-F1CD1C58D4CFQ30541002-8FAD7889-F0A9-479F-A948-E934F98D9102Q33814776-896E2468-E2B6-438C-A0D1-634DF4993EB4Q34422110-23D73681-1C1A-46A8-B123-D9659759EF10Q34558393-3BCA322D-8CC9-4375-8B95-78CEF8F51FD7Q34648178-060CBB43-FD25-4CB0-9B43-6BAF0EE35D66Q36256549-6B8405C8-D3C5-4CB7-AFA7-66F4530BACC6Q36345714-CF18617D-C483-4A7B-9CD0-D9CD60A5A0C4Q36762882-856D5BED-8DF1-438C-AC75-0F7C9C67A7B4Q37158481-982A52BD-9C6B-4C7F-BAA4-9D244C489956Q37205125-83274BE6-0D94-43C6-BA1C-200F9908B13AQ37476039-6B02A50D-AE9C-4A22-B691-98947056065CQ37629700-3DC8D541-FB9A-48E7-9182-79CF445A62ADQ38090495-20A062FA-E887-4B1D-8F36-301066A75FE8Q38123166-E71206AB-CE9B-4E59-828F-9753BB171CDBQ38214095-A35C445B-6E84-4A98-AC28-182561BD19ECQ38246769-55B4BE5A-F078-47DE-BABB-52A68389E86EQ38271877-CC04E955-3C8C-4872-8F02-671F85A9D124Q38305650-E22DB3F1-8319-4F46-B5E4-319AD2BC944EQ38473314-F05EC7F3-AD40-451E-8A81-F2CA00F01523Q38770814-E4690E4C-63A4-491A-B222-95D2268CA132Q38787696-E8DFEFDD-B632-4082-93EF-0F5F7C1EBD54Q38838643-49F0FC37-AC32-41DD-91E4-82C8CADE5FC0Q38948897-BEBD399E-6F1B-44D6-BCC3-B2E0BA782BACQ39013357-910A12F6-1CED-4D88-B7F1-7BE6CD698B6CQ47736893-0204C5DE-D333-428E-9356-FDFC6C679601Q48319918-DA9789F7-621B-4E1E-AB02-99A3056BD840Q54314072-ADDA082D-6164-43D1-B46D-BE0AA3937318
P2860
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@ast
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@en
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@nl
type
label
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@ast
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@en
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@nl
prefLabel
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@ast
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@en
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@nl
P2093
P2860
P356
P1476
Enhancement of anti-tumor immu ...... 4 and GITR by dendritic cells.
@en
P2093
David Boczkowski
Douglas S Tyler
Jens Dannull
Michael A Morse
N Rebecca Haley
Nicole de Rosa
Scott K Pruitt
Smita Nair
P2860
P304
P356
10.1002/EJI.201141383
P407
P577
2011-10-26T00:00:00Z